Jpmorgan Chase & CO Arbutus Biopharma Corp Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 80,727 shares of ABUS stock, worth $312,413. This represents 0.0% of its overall portfolio holdings.

Number of Shares

80,727

Previous 88,132 8.4%

Holding current value

$312,413

Previous $227,000 9.69%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$2.52 - $3.63 $18,660 - $26,880	-7,405 Reduced 8.4%	80,727 $249,000
Q1 2024 May 10, 2024	SELL	$2.26 - $2.92 $61,804 - $79,853	-27,347 Reduced 23.68%	88,132 $227,000
Q4 2023 Feb 12, 2024	SELL	$1.69 - $2.54 $5,950 - $8,943	-3,521 Reduced 2.96%	115,479 $288,000
Q3 2023 Nov 14, 2023	BUY	$1.9 - $2.27 $26,484 - $31,641	13,939 Added 13.27%	119,000 $241,000
Q2 2023 Aug 11, 2023	SELL	$2.24 - $3.06 $423,592 - $578,658	-189,104 Reduced 64.29%	105,061 $241,000
Q1 2023 May 18, 2023	BUY	$2.23 - $3.1 $194,081 - $269,799	87,032 Added 42.02%	294,165 $891,000
Q1 2023 May 11, 2023	BUY	$2.23 - $3.1 $299,464 - $416,295	134,289 Added 184.35%	207,133 $627,000
Q4 2022 Feb 13, 2023	BUY	$1.91 - $2.85 $5,940 - $8,863	3,110 Added 4.46%	72,844 $170,000
Q3 2022 Nov 14, 2022	BUY	$1.88 - $2.88 $10,420 - $15,963	5,543 Added 8.64%	69,734 $133,000
Q2 2022 Aug 11, 2022	BUY	$1.98 - $3.17 $10,424 - $16,690	5,265 Added 8.93%	64,191 $173,000
Q1 2022 May 11, 2022	BUY	$2.42 - $3.98 $39,177 - $64,432	16,189 Added 37.88%	58,926 $175,000
Q4 2021 Feb 10, 2022	BUY	$3.11 - $4.61 $15,941 - $23,630	5,126 Added 13.63%	42,737 $166,000
Q3 2021 Nov 12, 2021	BUY	$2.65 - $4.62 $99,669 - $173,762	37,611 New	37,611 $161,000

Others Institutions Holding ABUS

# of Institutions

138

Shares Held

95.4M

Call Options Held

3.44M

Put Options Held

377K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $580M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Arbutus Biopharma Corp Transaction History